Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals Incorporated    VRTX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Vertex Pharmaceuticals Incorporated : to Announce First Quarter 2017 Financial Results on April 27

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/20/2017 | 08:16pm CEST

By a News Reporter-Staff News Editor at Pharma Business Week -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2017 financial results on Thursday, April 27, 2017 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International) (see also Vertex Pharmaceuticals Incorporated).

The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website. About Vertex Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to our clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases.

Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For seven years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences. For additional information and the latest updates from the company, please visit www.vrtx.com.

(VRTX-WEB) View source version on businesswire.com: http://www.businesswire.com/news/home/20170412006017/en/

Keywords for this news article include: Vertex Pharmaceuticals Incorporated, Investment and Finance.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VERTEX PHARMACEUTICALS INC
04/20 VERTEX PHARMACEUTICALS INCORPORATED : to Announce First Quarter 2017 Financial R..
04/20 VERTEX PHARMACEUTICALS INCORPORATED : New Findings Reported from Vertex Pharmace..
04/13 IRONWOOD PHARMACEUTICALS : Appoints Dr. Christopher Wright as Senior Vice Presid..
04/12 VERTEX PHARMACEUTICALS INCORPORATED : to Announce First Quarter 2017 Financial R..
03/31 VERTEX PHARMACEUTICALS INCORPORATED : Biotech Stocks Under Scanner -- Rexahn Pha..
03/30 VERTEX PHARMACEUTICALS INCORPORATED : Based on new trial data, Vertex to seek ap..
03/29 Dave & Buster's declines while Vertex Pharmaceuticals jumps
03/29 VERTEX PHARMACEUTICALS INCORPORATED : (VRTX) Spikes on Release of Two Studies
03/29 NASDAQ 100 MOVERS : Biib, vrtx
03/29 S&P 500 MOVERS : Ffiv, vrtx
More news
Sector news : Bio Therapeutic Drugs
04/22DJNovartis Tests New Alzheimer's Drug on People Who Don't Have the Disease
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
04/20 Protalix BioTherapeutics Is Positioned Well For The Future
04/18 Is This Sudden Flight To Safety Temporary?
04/17 Concert Pharmaceuticals' Pipeline Has Strong Potential
04/17 MAYBE THE WORLD SHOULD SPEND MORE ON : Implications
04/17 WALL STREET BREAKFAST : Geopolitical Concerns Weigh On Markets
Advertisement
Financials ($)
Sales 2017 2 035 M
EBIT 2017 399 M
Net income 2017 129 M
Finance 2017 826 M
Yield 2017 -
P/E ratio 2017 176,76
P/E ratio 2018 52,71
EV / Sales 2017 13,8x
EV / Sales 2018 10,6x
Capitalization 28 993 M
More Financials
Chart VERTEX PHARMACEUTICALS INC
Duration : Period :
Vertex Pharmaceuticals Inc Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Full-screen chart
Technical analysis trends VERTEX PHARMACEUT...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 116 $
Spread / Average Target -0,93%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian F. Smith EVP, Chief Operating & Financial Officer
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Joshua S. Boger Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS..58.41%28 993
AMGEN, INC.9.71%118 044
CELGENE CORPORATION5.62%95 114
GILEAD SCIENCES, INC.-7.93%86 186
REGENERON PHARMACEUTIC..0.83%39 263
ACTELION LTD26.98%30 294
More Results